General
Preferred name
givinostat
Synonyms
ITF-2357 hydrochloride monohydrate ()
ITF2357 ()
Gavinostat hydrochloride monohydrate ()
Givinostat hydrochloride monohydrate ()
Givinostat hydrochloride ()
ITF2357 hydrochloride monohydrate ()
ITF 2357 ()
ITF2357 (Givinostat) ()
ITF-2357 ()
ITF-2357 hydrochloride ()
Givinostat (hydrochloride) ()
Givinostat (hydrochloride monohydrate) ()
Givinostat (ITF2357) ()
P&D ID
PD046520
CAS
732302-99-7
199657-29-9
497833-27-9
Tags
available
nuisance
drug
obsolete probe
Drug indication
Polycythemia vera
Essential thrombocythemia
Duchenne dystrophy
Myelofibrosis
Drug Status
approved
investigational
Max Phase
3.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Givinostat is a pan-histone deacetylase (HDAC) inhibitor . The clinically used formulation contains the hydrochloride (PubChem CID 52914048).
(GtoPdb)
DESCRIPTION
Givinostat (INN) or gavinostat, aslo known as ITF2357, is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis and polycythaemia vera. ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
High affinity JNK inhibitor; also inhibits HCMV replication
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
1
Compound Sets
18
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
Enamine BioReference Compounds
Guide to Pharmacology
Nuisance compounds in cellular assays
Obsolete Compounds
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
52
Molecular Weight
421.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
4.55
TPSA
90.9
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.37
Structural alerts
2
historic compounds (Chemical Probes.org)
Obsolete
Nonspecific HDAC inhibition
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Pathway
Chromatin/Epigenetic
DNA Damage/DNA Repair
NF-??b
Cell Cycle/DNA Damage
Epigenetics
Target
HD1-A
HD1-B
HD2
HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Primary Target
Non-selective HDACs
MOA
Inhibitor
HDAC inhibitor
Cellular injury category
HDAC
Source data
